12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Biocon, Pfizer deal

Biocon and Pfizer terminated a 2010 deal to market Biocon's biosimilar versions of insulin and insulin analog products, including recombinant human insulin, glargine, aspart and lispro. The companies said that "due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently." Pfizer said the termination is not related to Biocon's biosimilars deal with Mylan...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >